- Home
- LVLU vs KPTI Comparison
LVLU vs KPTI Comparison
Compare LVLU & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | KPTI |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 36.7M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LVLU | KPTI |
|---|---|---|
| Price | $11.48 | $0.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 9.7K | ★ 4.0M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,284,000.00 | $146,067,000.00 |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $357.61 | $27.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $4.37 | $0.31 |
| 52 Week High | $32.32 | $10.99 |
Technical Indicators
Market Signals| Indicator | LVLU | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 41.82 |
| Support Level | $9.01 | $0.31 |
| Resistance Level | $13.13 | $2.16 |
| Average True Range (ATR) | 1.29 | 0.14 |
| MACD | -0.18 | 0.10 |
| Stochastic Oscillator | 27.75 | 47.08 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates the majority of its revenue from customers based in the United States.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).